Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON33553
NL-OMON33553
Completed
Not Applicable

Sentinel Node and Recurrent Breast Cancer; Regional staging proposal and registration - SNARB

Catharina-ziekenhuis0 sites150 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRecurrent mammacarcinomabreast cancer10006291

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Recurrent mammacarcinoma
Sponsor
Catharina-ziekenhuis
Enrollment
150
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\-Operable cytological /histological confirmed locally recurrent breast cancer
  • •\-Having obtained an informed consent

Exclusion Criteria

  • •\-Proven ipsi\- or contralateral regional lymph node metastases (ultrasound and FNA)
  • •\-Known to be allergic to \*99mTc\-colloidal albumin\* or blue dye injection fluids

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 17.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2010-024477-39-GBBiogen Idec Limited1,600
Active, not recruiting
Phase 1
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2010-024477-39-GRBiogen Idec Limited1,600
Active, not recruiting
Not Applicable
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 17.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2010-024477-39-BEBiogen Idec Limited1,600
Completed
Phase 3
To determine if BIIB017 is safe and tolerable enough in patients with Relapsing Multiple Sclerosis on a long term duration.Health Condition 1: null- Multiple Sclerosis
CTRI/2011/12/002229Biogen Idec1,500
Active, not recruiting
Not Applicable
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
EUCTR2010-024477-39-ESBiogen Idec Limited1,600